CROI 2015 Program and Abstracts

Poster Listings

581 WITHDRAWN 582 Impact of Specific Antiretroviral Drugs on Non-AIDS Mortality; the D:A:D Study Camilla I. Hatleberg 1 ; Lene Ryom 1 ; Andrew N. Phillips 2 ; Amanda Mocroft 2 ; Peter Reiss 3 ; Matthew Law 4 ; RainerWeber 5 ; François Dabis 6 ; Jens D. Lundgren 1 ; Colette Smith 2 On behalf of the D:A:D Study group 1 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 2 University College London, London, United Kingdom; 3 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 4 University of New South Wales, Sydney, Australia; 5 University Hospital Zurich, Zurich, Switzerland; 6 University of Bordeaux, Bordeaux, France 583 HIV-Related Causes of Death in the Era of Antiretroviral Therapy: Analysis of Verbal Autopsy Data Clara Calvert 1 ; Zehang Li 2 ;Tyler McCormick 2 ; Alison Price 1 ; Kobus Herbst 4 ; Denna Michael 3 ; Estelle McLean 1 ; Basia Zaba 1 ; Samuel Clark 2 On behalf of the ALPHA network 1 London School of Hygiene and Tropical Medicine, London, United Kingdom; 2 University of Washington, Seattle, WA, US; 3 National Institute for Medical Research, Mwanza, United Republic of Tanzania; 4 Africa Centre for Health and Population Studies, Mtubatuba, South Africa 584 Facility-Level Factors AssociatedWith Mortality of Patients on ART: A Retrospective Cohort Study in Kenya, 2007-2012 Emily A. Dansereau 1 ; Allen Roberts 1 ; Herbert C. Duber 1 ; Gregoire Lurton 1 ; Brendan DeCenso 2 ;Thomas Odeny 1 ; Samuel Masters 3 ; Roy Burstein 1 ; Pamela Njuguna 1 ; Emmanuela Gakidou 1 1 University of Washington, Seattle, WA, US; 2 RTI International, Raleigh, NC, US; 3 University of North Carolina, Chapel Hill, NC, US 2:30 pm– 4:00 pm HIV Drug Resistance: Mechanisms and Mutations 585 Structural Basis of Inhibition and Resistance Mechanism to EFdA, a Highly Potent NRTI Zhe Li 1 ; Karen Kirby 1 ; Bruno Marchand 1 ; Michailidis Eleftherios 1 ; Eiichi Kodama 2 ; Hiroaki Mitsuya 3 ; Michael Parniak 4 ; Stefan Sarafianos 1 1 University of Missouri, Columbia, MO, US; 2 Tohoku University, Sendai, Japan; 3 National Institutes of Health, Division of AIDS, Bethesda, MD, US; 4 University of Pittsburgh, Pittsburgh, PA, US 586 Structural Basis and Distal Effects of Gag Substrate Coevolution in Drug Resistance to HIV-1 Protease Kuan-Hung Lin ; Celia A. Schiffer University of Massachusetts Medical School, Worcester, MA, US 587 Influence of Codon Pair Usage in the Evolvability of HIV-1 Maria Nevot ; Cristina Andrés; Mariona Parera; Glòria Martrus; Miguel Ángel Martínez IrsiCaixa Institute for AIDS Research, Badalona, Spain 588 Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide PI Susceptibility Dana N. Raugi 1 ; Robert A. Smith 1 ; Matthew Coyne 1 ; Julia Olson 1 ; Kara Parker 1 ; Selly Ba 2 ; Papa Salif Sow 2 ; Moussa Seydi 2 ; Geoffrey S. Gottlieb 1 University ofWashington-Dakar HIV-2 Study Group 1 University of Washington School of Medicine, Seattle, WA, US; 2 Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Dakar, Senegal 589 Enhanced Neutralization of HIV-1With Fusion Inhibitor Resistant Mutations Muntasir Alam 1 ;Takeo Kuwata 1 ; Kristel P. Ramirez 1 ;Yasuhiro Maruta 1 ; KazukiTanaka 1 ; Kazuya Shimura 2 ; Shinya Oishi 2 ; Nobutaka Fujii 2 ; Masao Matsuoka 2 ; Shuzo Matsushita 1 1 Kumamoto University, Kumamoto, Japan; 2 Kyoto University, Kyoto, Japan THURSDAY, FEBRUARY 26, 2015 Session P-L1 Poster Session Poster Hall

590 Mutations at the Bottom of the Phe43 Cavity Are Responsible for Cross- Resistance to NBD Analogues Shigeyoshi Harada 1 ;Yu Irahara 2 ; Samatchaya Boonchawalit 1 ; Mai Goryo 1 ; Hirokazu Tamamura 2 ;Tetsuro Matano 1 ; Shuzo Matsushita 3 ; KazuhisaYoshimura 1 1 National Institute of Infectious Diseases, Shinjuku, Japan; 2 Tokyo Medical and Dental University, Chiyoda, Japan; 3 Kumamoto University, Kumamoto, Japan 591 SIV mac239 Integrase as a Model of HIV Drug Resistance Against Integrase Inhibitors Said Hassounah 1 ;Thibault Mesplede 1 ; Maureen Oliveira 1 ; Peter K. Quashie 1 ; Daniela Moisi 1 ; Paul A. Sandstrom 2 ; Mark A.Wainberg 1 ; Bluma Brenner 1 1 McGill University, Montréal, Canada; 2 National HIV and Retrovirology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Ottawa, Canada 592 Within-Run Cross-Contamination in Deep Sequencing Applications on the Illumina MiSeq Chanson J. Brumme ;Winnie Dong; Celia K. Chui; Richard Liang; Art F. Poon; Richard Harrigan BC Centre for Excellence in HIV/AIDS, Vancouver, Canada 593 Analysis of Resistance Haplotypes Using Primer IDs and Next Gen Sequencing of HIV RNA Valerie F. Boltz 1 ; Jason Rausch 1 ;Wei Shao 2 ; Charles Coomer 1 ; JohnW. Mellors 3 ; Mary Kearney 1 ; John M. Coffin 4 1 National Institutes of Health (NIH), Frederick, MD, US; 2 Leidos, Frederick, MD, US; 3 University of Pittsburgh, Pittsburgh, PA, US; 4 Tufts University, Boston, MA, US Session P-L2 Poster Session Poster Hall 2:30 pm– 4:00 pm HIV Subtypes and Resistance 594 HIV-1 Subtype Influences the Pathways of Genotypic Resistance to Integrase Inhibitors Tomas J. Doyle 1 ; David Dunn 4 ; Rolf Kaiser 3 ; Erasmus Smit 10 ; Anne-Genevieve Marcelin 5 ; Carmen de Mendoza 6 ; Javier Martínez-Picado 9 ; Federico Garcia 7 ; Francesca Ceccherini- Silberstein 8 ; Anna Maria Geretti 2 CORONET study group 1 King’s College London, London, United Kingdom; 2 University of Liverpool, Liverpool, United Kingdom; 3 University of Cologne, Cologne, Germany; 4 University College London, London, United Kingdom; 5 Hôpital Pitié Salpetriere, APHM, Paris, France; 6 Hospital Carlos III, Madrid, Spain; 7 University Hospital San Cecilio, Granada, Spain; 8 University of Rome Tor Vergata, Rome, Italy; 9 Institut de Recerca de la Sida, Barcelona, Spain; 10 Birmingham Heartlands Hospital, Birmingham, United Kingdom 595 Differences in Resistance Mutations in Non-B Subtypes at First-Line Failure in Africa Cissy M. Kityo 1 ; SarahWalker 2 ; Immaculate Nankya 1 ; Anne Hoppe 2 ; JenniferThompson 2 ; Silvia Bertagnolio 3 ; Philippa Easterbrook 3 ; Peter Mugyenyi 1 ; Nicholas Paton 4 On behalf of the EARNESTTrialTeam 1 Joint Clinical Research Centre, Kampala, Uganda; 2 MRC Clinical Trials Unit at University College London, London, United Kingdom; 3 World Health Organization, Geneva, Switzerland; 4 Yong Loo Lin School of Medicine, Singapore, Singapore 596 K65R Detected More Frequently in HIV-1 Subtype C Viruses at Virological Failure Erasmus Smit 1 ; EllenWhite 7 ; Duncan Clark 4 ; Duncan Churchill 2 ; Hongyi Zhang 6 ; Simon Collins 5 ; Deenan Pillay 3 ; AnnaTostevin 7 ; David Dunn 7 UKHDRD and UKCHIC 1 Public Health England, Birmingham, United Kingdom; 2 Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 3 University of KwaZulu-Nata and University College London, London, United Kingdom; 4 St Batholomew’s and the London NHS Trust, London, United Kingdom; 5 HIV i-Base, London, United Kingdom; 6 Addenbrooke’s Hospital, Cambridge, United Kingdom; 7 University College London, London, United Kingdom 597 Viral Failure and High K65R in Kenyan Patients on Tenofovir-Based First- Line Therapy Katherine C. Brooks 2 ; Lameck Diero 1 ; Allison Delong 2 ; Maya Balamane 2 ; Marissa Reitsma 2 ; Emmanuel Kemboi 3 ; Millicent Orido 3 ; Mia Coetzer 2 ; Joseph Hogan 2 ; Rami Kantor 2 1 Moi University, Eldoret, Kenya; 2 Brown University, Providence, RI, US; 3 Academic Model Providing Access to Healthcare, Eldoret, Kenya

Poster Listings

48

CROI 2015